Alkermes (NASDAQ:ALKS) is a biopharmaceutical company focused on developing innovative medicines that aim to address unmet needs in the treatment of central nervous system (CNS) disorders, such as schizophrenia, depression, and addiction. The company is actively involved in various stages of research, development, and commercialization of a broad portfolio of drugs. With a commitment to improving patient outcomes, Alkermes undertakes projects that stretch from early-stage discovery to clinical trials, striving to bring new therapies to market. Their objectives are centered around leveraging their scientific expertise and technological platforms to create therapies that can make a significant difference in patients' lives, while also seeking to expand their market presence and enhance shareholder value through strategic initiatives and collaborations.